CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Watchman FLX Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05324371
NCT05324371N/ACompleted
CompareCT.gov

A Pilot Study to Assess WATCHMAN FLX™ Implants by Cardiac Computed Tomography, Magnetic Resonance Imaging and Transesophageal Echocardiography: WATCHMAN FLX™ CT

Boston Scientific Corporation·interventional·Posted Apr 12, 2022·Updated Jul 1, 2025

In Brief

A clinical study evaluating Watchman FLX Device for The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation. Completed, enrolled 25 participants across 1 site.

Detailed Summary

WATCHMAN FLX™ CT is a prospective, single-arm, single-center, post-market investigation to assess device tissue coverage in subjects with non-valvular atrial fibrillation (AF) who receive the WATCHMAN FLX device to reduce the risk of stroke. Serial advanced imaging modalities such as CT and TEE will be used.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThe Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation
CountriesDenmark
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 12, 2022
Enrollment StartNov 9, 2022
Primary CompletionMay 30, 2024
Study CompletionJan 23, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.2 years ago

Interventions

Watchman FLX Devicedevice

Left atrial appendage closure using the Watchman FLX device